GEN Exclusives

More »

GEN News Highlights

More »
May 15, 2012

Gamida Cell Raises $10M to Progress Phase III-Stage Hematologic Cancer Cell Therapy

  • Gamida Cell raised $10 million through an internal Series E financing round with all its existing major shareholders. The proceeds will be used to support global commercialization of the firm’s Phase III-stage StemEx cord blood stem cell therapy for blood cancers, and continue development of additional pipeline candidates, including clinical development of its cord blood-based NiCord® cell therapy for the treatment of sickle cell disease and thalassemia.

    StemEx is an expanded stem cell product in development through a joint venture with Teva as an alternative allogeneic therapy for patients with blood cancers such as leukemia and lymphoma who could be cured by bone marrow transplantation but for whom there is no matched bone marrow donor available. Results from the ongoing registrational study are expected by the end of 2012, and market launch of StemEx is projected for 2013.

    StemEx comprises a graft of expanded stem/progenitor cells derived from a single umbilical cord blood unit, and transplanted by IV administration together with the remaining cells from the same cord blood unit. Gamida Cell says that in contrast with competing cord blood-derived products in development that use two units of blood, StemEx should be significantly less expensive. The firm is currently looking for a strategic partner for global commercialization of the product.

    Gamida Cell’s remaining pipeline is based on its nicotinamide (NAM) stem cell expansion platform. The lead NAM-based product NiCord is in Phase I/II clinical development for the potential treatment of hematologic malignancies and hemoglobinopathies such as sickle cell disease and thalassemia. The NAM technology also forms the basis of the firm’s CordBridge™ candidate for treating neutropenia, and is being applied to natural killer cell expansion to develop products for solid and hematological cancers, and to mesenchymal stem cells for applications in regenerative medicine. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?